Alebund Pharmaceuticals (Jiangsu) Limited
禮邦醫藥（江蘇）股份有限公司
- Listing
- HKEX 09637
Clinical-stage assets
| Asset | Phase / approval scope | Indication | Source date |
|---|---|---|---|
| AP306 (EOS789) | Phase IIa completed; Phase IIb planned at announcement | Hyperphosphatemia in chronic kidney disease receiving dialysis | 2026-03-17 |
Licensing announcements since 2025
| Date | Counterparty | Asset / platform | Upfront | Near-term | Potential total | Stage at announcement |
|---|---|---|---|---|---|---|
| 2026-03-17 | R1 Therapeutics, Inc. | AP306 (EOS789) | Phase IIa completed; Phase IIb planned at announcement |